Disease · HP_0001685
Myocardial fibrosis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Myocardial fibrosis. Diseases, record HP_0001685. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001685
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Myocardial fibrosis
- Open Targets ID
- HP_0001685
- Highest stage of its drugs
- Phase 3, for 4 of its 8 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SPIRONOLACTONE | CHEMBL1393 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DAPAGLIFLOZIN | CHEMBL429910 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIHYDRALAZINE | CHEMBL35505 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ENALAPRIL | CHEMBL578 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LOSARTAN | CHEMBL191 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PIRFENIDONE | CHEMBL1256391 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ATORVASTATIN | CHEMBL1487 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC5A2 | Sodium/glucose cotransporter 2 | 2 | Sodium/glucose cotransporter 2 inhibitor | Phase 3 | https://conductscience.org/library/genes/6524 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 1 | Angiotensin-converting enzyme inhibitor | Phase 3 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 1 | Type-1 angiotensin II receptor antagonist | Phase 2 | https://conductscience.org/library/genes/185 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 1 | HMG-CoA reductase inhibitor | Unknown | https://conductscience.org/library/genes/3156 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 1 | Mineralocorticoid receptor antagonist | Phase 3 | https://conductscience.org/library/genes/4306 | Drugs and targets |
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02285920 | Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial | Phase 2 | 129 | 2019-07-23 | End-Stage Renal Disease | SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov |
| NCT01150461 | Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy | Phase 2 | 20 | 2013-09-05 | Hypertrophic Cardiomyopathy | LOSARTAN | Its record names the disease | ClinicalTrials.gov |
| NCT05230901 | Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden | Phase 3 | 300 | Aortic Stenosis, Severe | DIHYDRALAZINE, SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov | |
| NCT06469645 | The Role of SGLT2i in Management of Moderate AS | Phase 2/3 | 104 | Moderate Aortic Valve Stenosis | EMPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05531955 | Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial Infarction | Phase 2 | 100 | Myocardial Fibrosis | PIRFENIDONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02432885 | Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial | Phase 3 | 76 | Myocardial Fibrosis, Muscular Dystrophies | ENALAPRIL | Its record names the disease | ClinicalTrials.gov | |
| NCT06619600 | Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction | Phase 3 | 54 | ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Heart Failure, Myocardial Fibrosis | DAPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00172419 | The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients. | Not applicable | 43 | Hyperlipidemia | ATORVASTATIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Losartan 50 PO mg BID vs Placebo: serious adverse events | 0 of 11 | 0 of 9 | 20 | NCT01150461 |
Source Trial comparisons
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001685
GET https://conductscience.org/api/diseases/v1/HP_0001685/drugs